Synergy Pharma (SGYP) Posts Q1 Loss of 18c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Aegis Trims PT on Synergy (SGYP) to $26 Following Q1 Results; Updates on N-T Catalysts
May 14, 2014 10:02 AM EDTAegis Capital cuts its price target on Synergy Pharmaceuticals (Nasdaq: SGYP) from $28 down to $26 while affirming its Buy rating.
Analyst Ram Selvaraju noted that Synergy's Q1 loss of $.18 per share was narrower than his expected loss of $.23 per share, based on lower R&D and G&A spending.
Selvaraju also highlighted near-term catalysts for... More
